Stryker Price To Earning vs. Revenue
| SYK Stock | EUR 369.30 0.40 0.11% |
For Stryker profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Stryker to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Stryker utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Stryker's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Stryker over time as well as its relative position and ranking within its peers.
Stryker |
Stryker Revenue vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Stryker's current stock value. Our valuation model uses many indicators to compare Stryker value to that of its competitors to determine the firm's financial worth. Stryker is currently regarded as top stock in price to earning category among its peers. It also is currently regarded number one company in revenue category among its peers totaling about 902,592,955 of Revenue per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Stryker's earnings, one of the primary drivers of an investment's value.Stryker Revenue vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Stryker |
| = | 20.44 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Stryker |
| = | 18.45 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Stryker Revenue vs Competition
Stryker is currently regarded number one company in revenue category among its peers. Market size based on revenue of Medical Devices industry is at this time estimated at about 51.89 Billion. Stryker totals roughly 18.45 Billion in revenue claiming about 36% of all equities under Medical Devices industry.
Stryker Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Stryker, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Stryker will eventually generate negative long term returns. The profitability progress is the general direction of Stryker's change in net profit over the period of time. It can combine multiple indicators of Stryker, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 36000 people.
Stryker Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Stryker. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Stryker position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Stryker's important profitability drivers and their relationship over time.
Use Stryker in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Stryker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stryker will appreciate offsetting losses from the drop in the long position's value.Stryker Pair Trading
Stryker Pair Trading Analysis
The ability to find closely correlated positions to Stryker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Stryker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Stryker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Stryker to buy it.
The correlation of Stryker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Stryker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Stryker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Stryker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Stryker position
In addition to having Stryker in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cancer Fighters Thematic Idea Now
Cancer Fighters
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Stryker Stock
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map. For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
To fully project Stryker's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Stryker at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Stryker's income statement, its balance sheet, and the statement of cash flows.